Cipla inches up as its affiliate enters into strategic partnership with SIGA Technologies
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cipla is currently trading at Rs. 777.80, up by 5.00 points or 0.65% from its previous closing of Rs. 772.80 on the BSE.
The scrip opened at Rs. 779.00 and has touched a high and low of Rs. 779.00 and Rs. 773.00 respectively. So far 7905 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 878.55 on 03-Feb-2021 and a 52 week low of Rs. 371.65 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 795.60 and Rs. 738.25 respectively. The current market cap of the company is Rs. 62323.26 crore.
The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 40.05% and 23.25% respectively.
Cipla Therapeutics, a division of Cipla USA, Inc., an affiliate of Cipla and SIGA Technologies, Inc. (SIGA) have entered into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.
The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity 2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism (such as bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it. It is an increasingly significant threat to global public health which is present in every country around the world and infections caused by drug-resistant bacteria can cause death.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
